You are here

cancer

Bayer acquires full Vitrakvi rights from Eli Lilly's Loxo

Bayer acquires full Vitrakvi rights from Eli Lilly's Loxo

Yahoo/Reuters

Flag link:

HaiHe raises $147M to advance cancer candidates

HaiHe raises $147M to advance cancer candidates

BioCentury

Shanghai HaiHe Biopharma

Flag link:

Sanofi Cuts a Whopping 38 R&D Programs to Refocus on Cancer, Immunology, and Rare Diseases

Sanofi Cuts a Whopping 38 R&D Programs to Refocus on Cancer, Immunology, and Rare Diseases

BioSpace

Flag link:

HiberCell Launches With $60 Million on Mission to Prevent Cancer Relapse and Metastasis

HiberCell Launches With $60 Million on Mission to Prevent Cancer Relapse and Metastasis

CP Wire

metastatic cancer

Flag link:

The bispecific boom: Genentech pays $120M to tie the knot with Xencor on an IL-15 alliance

The bispecific boom: Genentech pays $120M to tie the knot with Xencor on an IL-15 alliance

Endpoints

bispecific antibodies

Flag link:

Can Digital Medicine Improve Drug Adherence?

Can Digital Medicine Improve Drug Adherence?

Forbes

patient adherence

Proteus Digital Health

Flag link:

Israeli Scientists Say They Will Have A Complete Cure For Cancer Within A Year

Israeli Scientists Say They Will Have A Complete Cure For Cancer Within A Year

Forbes

Accelerated Evolution Biotechnologies

Flag link:

Pfizer’s Cancer Portfolio Expected to Rake in $8.3 Billion in 2019

Pfizer’s Cancer Portfolio Expected to Rake in $8.3 Billion in 2019

BioSpace

Flag link:

A two-fisted punch against cancer metastasis

A two-fisted punch against cancer metastasis

Fierce Biotech

Duke University

Flag link:

In another setback for Eli Lilly, FDA follows EMA in calling for a halt to new Lartruvo prescriptions

In another setback for Eli Lilly, FDA follows EMA in calling for a halt to new Lartruvo prescriptions

Endpoints

Flag link:

How to stop a lack of diversity undermining clinical trial data

How to stop a lack of diversity undermining clinical trial data

Financial Times

clinical trials

Flag link:

Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup

Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup

Bizjournals

drug development

Kyn Therapautics

Flag link:

Blocking PD-L1 production in mice, UCSF team spotlights preclinical promise of a Pfizer-partnered I/O drug

Blocking PD-L1 production in mice, UCSF team spotlights preclinical promise of a Pfizer-partnered I/O drug

Endpoints

immuno-oncology

Flag link:

In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica

In a first, China’s BeiGene scores FDA ‘breakthrough’ status for BTK inhibitor — potential rival for Imbruvica

Endpoints

Flag link:

Liquid biopsy-based system could prevent cancer from spreading

Liquid biopsy-based system could prevent cancer from spreading

Pharmaforum

metastic cancer

Flag link:

Black Diamond Gets $85M for Cancer Drugs R&D and New Cambridge HQ

Black Diamond Gets $85M for Cancer Drugs R&D and New Cambridge HQ

Xconomy

Black Diamond Therapeutics

Flag link:

For CAR-T Cancer Fighters in the Real World, Two Roads Diverge

For CAR-T Cancer Fighters in the Real World, Two Roads Diverge

Xconomy

Gilead Sciences

Flag link:

New Clinical Trial Aims To Detect Cancer With A Quick Breathalyser Test

New Clinical Trial Aims To Detect Cancer With A Quick Breathalyser Test

Forbes

clinical trials

Owlstone Medical

Flag link:

Pharma's 2019 Prognosis Hinges on These Key Themes

Pharma's 2019 Prognosis Hinges on These Key Themes

Bloomberg

Flag link:

Deciphera expands cancer trial after seeing early data

Deciphera expands cancer trial after seeing early data

Fierce Biotech

clinical trials

Flag link:

Pages